Herve Hubert
About Herve Hubert
Herve Hubert is the US Pricing & Contracting Strategy Lead Hematology at Bristol-Myers Squibb, with extensive experience in pricing strategy and market access in the pharmaceutical industry.
Current Role at Bristol-Myers Squibb
Herve Hubert is currently serving as the US Pricing & Contracting Strategy Lead for Hematology at Bristol-Myers Squibb in the Greater New York City Area. In this role, he has been responsible for leading the US launch pricing and contracting strategy for significant medications such as Reblozyl (MDS) and Onureg (AML) in the lymphoma therapeutic area. Hubert has also contributed to the development of the loss of exclusivity (LOE) contracting strategy for Revlimid and has led US pricing for CAR-T/Cell therapy products like Breyanzi and Abecma.
Previous Roles at Sanofi
Before joining Bristol-Myers Squibb, Herve Hubert had an extensive tenure at Sanofi from 1995 to 2019, where he held multiple strategic roles. These included Global Pricing Strategy Lead for MS, Immunology & Oncology, and Director of US Strategic Pricing & Market Access. Hubert also worked as a Global Early Pricing Director for Biologics and held positions in contract management and strategic control within the oncology division. His initial positions at Sanofi involved roles in market research analysis and product management.
Educational Background
Herve Hubert has a robust educational background in pharmaceutical sciences and marketing. He received his Pharm D degree from Université Paris Cité, where he studied from 1989 to 1996. He also earned a Master's in Chemical Synthesis of Therapeutics Entities from Université René Descartes (Paris V) and another Master’s in Pharmaceutical Marketing from Université Paris Cité. Additionally, Hubert participated in continuous internal training at Sanofi from 1997 to 2009, further sharpening his industry expertise.
Expertise in Pricing and Contracting
Herve Hubert has demonstrated significant expertise in the realms of pricing and contracting strategies, particularly within the pharmaceutical industry. His experience includes early launch pricing for products like CelMods Iberdomide and the strategic management of loss of exclusivity (LOE) for drugs such as Revlimid. Hubert has developed and led innovative pricing strategies while managing cross-functional teams across various domains including R&D, medical, marketing, finance, and operations.